Nohla will use Karius' NGS plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
With fewer rules, doctors in China are moving ahead with CRISPR clinical trials, the Wall Street Journal reports.
Stat News reports that researchers are not good at predicting whether a clinical trial will be successful.
Riken researchers conducting a trial of an iPS cell treatment of age-related macular degeneration say a patient experienced swelling, according to the Japan Times.
CRISPR Therapeutics is moving toward clinical trials for beta thalassemia and sickle cell disease treatments, according to Wired.
In a Phase III trial, talazoparib-treated patients had a three-month median progression-free survival advantage over patients treated with chemotherapy chosen by their doctors.
At the San Antonio Breast Cancer Symposium, Myriad reported on the ability of its 86 SNP score to predict disease risk for the majority of women of European ancestry.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.